



2019 Cardiovascular Summit for Primary Care

Thursday 21st & Friday 22nd March 2019

Lisbon, Portugal

Scientific programme endorsed by WONCA Europe. EPCCS is a Special Interest Group (SIG) of WONCA Europe and WONCA World

The summit will cover major issues in a sessional debate format with focused clinical update talks. The main debate sessions will present the most up to date evidence on a range of key cardiovascular topics and what this means for clinical primary care practice, concluding with what evidence should be implemented, where uncertainties remain, and how we should deal with this. Outputs from EPCCS 2019 will become key points on our website, with video sessions, free-standing papers, and guidance documents, translated where possible. The main output will be an EPCCS Value evidence Into Practice (VIP) reference guide for each topic presented at the Summit.

Agenda

Thursday, March 21, 2019

11:00 – 11:10	Welcome, opening remarks	Prof Richard Hobbs Oxford, United Kingdom
Session 1	Workshop on the challenges of Multi-Morbidity <i>Roving Session Chair: Dr Monika Hollander, Utrecht, The Netherlands</i> <i>Case based discussions to illustrate and debate the challenges of multi-morbidity in patients with vascular disease</i>	
11:10 – 11:40	Case 1: CVD and mental health	Prof. Christos Lionis Crete, Greece
11:40 – 12:10	Case 2: Multimorbidity, CVD disease and polypharmacy	David Silvério Rodrigues, Lisbon, Portugal
12:10 – 12:30	Discussion	
12:30 – 13:15	Lunch break	
Session 2	Update on stroke prevention in atrial fibrillation <i>Roving session chair: Dr Michaela Macháčová, Bratislava</i>	
13:15 – 14:00	What's the evidence and options from the guidelines?	Prof Richard Hobbs
14:00 – 14:30	Audience debate	

Session 3

14:30 – 15:20

EPCCS Rapid Abstract Session:

Freestanding abstracts from EPCCS members
5 sessions of 10 minutes each (5 + 5 mins)

The Tip of the Iceberg: Finding Patient with Heart Failure with Preserved Ejection Fraction in Primary Care

Christi Deaton – United Kingdom

Analytical and clinical performance of 5 recently introduced POC D-dimer analysers to rule-out Venous Thrombo-Embolism in primary care

Jorn Heerink – The Netherlands

Survival rates in chronic heart failure: A systematic review and meta-analysis

Nicholas Jones – United Kingdom

The HAS-BLED score as a possible prognosis score of intracerebral haemorrhage -

Blanca Lorman – Spain

Analysis of the Relationship Between the Expectations of Patients with Cardiovascular Disease and the Quality of Life Level

Elzbieta Szlenk-Czyczerska - presented by **Donata Kurpas** – Poland

15:20 – 15:45

Break, & posters**Session 4**

Recent updates to the International Hypertension guidelines – Where do they vary and what should we agree in primary care?

Roving Session Chair: Prof Christos Lionis, Crete, Greece

- Is hypertension still important to cardiovascular disease prevention?
- Why don't the guidelines agree?
- What has changed in the evidence base?
- What should GPs do?

15:45 – 16:30

What's the evidence, why guidelines differ, and what should the GP do?

Prof Richard McManus
Oxford, United Kingdom

16:30 – 17:00

Panel & audience debate on main issues

17:00 – 17:30

What are remaining questions for primary care and consensus summary?

Session Chair & Main speaker**Friday, March 22, 2019****Session 5****Complexities of managing Heart Failure**

Roving Session Chair: Dr Monika Hollander

- *Do we diagnose and monitor heart failure effectively?*
- *What is the importance of co-morbidities?*
- *What about palliative care?*
- *Is there new evidence?*

09:00 – 09:30	Heart failure and co-morbidities – impact on diagnosis and management	Peter van der Meer Groningen, The Netherlands
09:30 – 10:00	Update on management issues in heart failure	Peter van der Meer
10:00 – 10:30	Panel & audience debate on main issues	
10:30 – 10:45	What are remaining questions for primary care and consensus summary?	
10:45 – 11:05	<i>Break & Posters</i>	
Session 6	Diabetes and cardiovascular risk <i>Roving session chair: Dr Carlos Brotons, Barcelona, Spain</i>	
	<ul style="list-style-type: none"> ● <i>do the novel anti-diabetes medications offer new options?</i> ● <i>What are the main issues for GPs?</i> <p>What is the evidence for diabetes and risk of vascular disease? Can we quantify that risk? Is there evidence for interventions that can modify this risk and, if so, how are these interventions are initiated, dosed, and monitored, alongside any adverse effects and contra-indications? There are many recent and new data to guide this symposium</p>	
11:05 – 11:20	What's the evidence that diabetes is linked to CVD?	Prof Richard Hobbs
11:20 – 12:05	Update on managing CV risk in diabetes – what's the evidence?	Prof Kamlesh Khunti, Leicester, United Kingdom
12:05 – 12:35	Panel & audience debate	
12:35 – 12:50	What are remaining questions for primary care and consensus summary?	Session Chair & Main speaker
12:50 – 13:30	<i>Lunch Break</i>	
Session 7	EPCCS: CVD & The Primary Care Challenge <i>Roving session chair: Prof Richard Hobbs</i>	
13:30 – 14:15	Setting priorities for clinical practice in CVD Open forum and workshop	
14:15 - 14.45	Feedback on EPCCS CV Summit 2019 & Closing	